Table 2:

Multivariable model evaluating exposures between conditioning start and day +7 with grade II-IV acute GVHD in the full cohort

	aOR	95% CI	p value
Primary Exposure Variables
Cephalosporins (ref: none)	1.05	0.83-1.32	0.710
Penicillins (ref: none)	1.24	0.93-1.66	0.140
Carbapenems (ref: none)	1.24	1.02-1.51	0.035
Covariates included in model
Other antibiotics without anti-anaerobic coverage (ref: none)	1.03	0.84-1.26	0.780
Other antibiotics with anti-anaerobic coverage (ref: none)	1.08	0.89-1.30	0.430
Fluoroquinolones (ref: none)	1.12	0.85-1.49	0.410
Vancomycin (ref: none)	1.01	0.82-1.22	0.960
Receipt of thymoglobulin/alemtuzumab (ref: none)	0.69	0.52-0.90	0.008
Receipt of growth factors (ref: none)	1.19	0.89-1.61	0.250
Graft source (ref: bone marrow)			0.044
Peripheral blood	1.49	1.09-2.04	0.014
d	0.83	0.55-1.26	0.380
Conditioning (ref: myeloablative with TBI)			0.056
Myeloablative with no TBI	0.75	0.61-0.92	0.007
Reduced intensitity	1	0.72-1.40	0.990
Donor (ref: matched related)			0.002
Matched unrelated	1.13	0.92-1.40	0.240
Mismatched unrelated	1.83	1.47-2.28	<.001
Haploidentical	0.99	0.71-1.40	0.970
GVHD Prophylaxis (ref: calcineurin inhibitor based)			0.084
ex-vivo T cell depletion	0.61	0.40-0.95	0.027
Other	1.05	0.64-1.74	0.840

GVHD Graft versus Host Disease; aOR adjusted Odds Ratio; CI Confidence Interval; TBI Total Body Irradiation